Literature DB >> 35634432

Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Alessandro Rizzo1, Angela Dalia Ricci1, Giovanni Brandi1.   

Abstract

Entities:  

Year:  2021        PMID： 35634432      PMCID： PMC9109071          DOI： 10.1159/000520481

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   12.430


× No keyword cloud information.
  5 in total

1.  Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-02-15       Impact factor: 11.740

2.  A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-03-05       Impact factor: 11.740

3.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

4.  Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.

Authors:  J P T Higgins; D Jackson; J K Barrett; G Lu; A E Ades; I R White
Journal:  Res Synth Methods       Date:  2012-06       Impact factor: 5.273

5.  Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis.

Authors:  Arndt Vogel; Lorenza Rimassa; Hui-Chan Sun; Ghassan K Abou-Alfa; Anthony El-Khoueiry; David J Pinato; Javier Sanchez Alvarez; Monica Daigl; Panos Orfanos; Michael Leibfried; Marie-Hélène Blanchet Zumofen; Vincent E Gaillard; Philippe Merle
Journal:  Liver Cancer       Date:  2021-05-06       Impact factor: 11.740
  5 in total
  1 in total

1.  Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma.

Authors:  Xinyao Hu; Hua Zhu; Shi Feng; Chaoqun Wang; Yingze Ye; Xiaoxing Xiong
Journal:  Front Genet       Date:  2022-09-29       Impact factor: 4.772
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.